Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
Questo articolo non è rilevante per Warptech Tech News — è medico/pharma (approvazione FDA di un farmaco oncologico), non tech/AI/business. Puoi mandarmi un articolo tech-relato da riassumere secondo le regole editoriali?
— Capivasertib plus abiraterone combination lands indication for PTEN-deficient tumors
by Ian Ingram, Managing Editor, MedPage Today
June 12, 2026
• 2 min read
The FDA approved capivasertib (Truqap) in combination with abiraterone (Zytiga) and prednisone for PTEN-deficient prostate cancer, the agency announced on Friday.
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer
This Aggressive Prostate Cancer Finally Has Targeted Treatment — AstraZeneca Wins FDA Nod - AstraZeneca (
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
Vopimetostat-daraxonrasib combo ‘extremely encouraging’ in metastatic pancreatic cancer
FDA approves belzutifan with pembrolizumab as adjuvant for renal cell carcinoma
FDA approves Merck's Welireg-Keytruda combo as adjuvant treatment for kidney cancer
TRUQAP® (capivasertib) combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic…
Major FDA wins for AstraZeneca: Truqap combination approved for advanced prostate cancer; Ultomiris kidney disease drug gets…
Una nuova combinazione di farmaci sarà presto disponibile per il trattamento dei pazienti con tumore della prostata…
Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alterations
At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.
Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer. | After winning a…
